Literature DB >> 6431443

Immunochemical characterization of factor VIII inhibitors.

L W Hoyer, M S Gawryl, B de la Fuente.   

Abstract

Factor VIII inhibitors are antibodies, predominantly of the IgG class, that inactivate factor VIII procoagulant activity. They do not fix complement and cannot be detected by standard immunoprecipitin assays. Their immunochemical properties are unusual, for the alloantibodies have consistent light chain restriction (kappa) and most allo- and auto- anti-VIII:C are predominantly or exclusively IgG4. This property may be responsible for the lack of complement fixation and immunoprecipitation. Human anti-VIII:C react with several different VIII:C antigenic determinants, and recent studies have begun to characterize the major epitopes. In addition, anti-VIII:C idiotypes have been identified using both rabbit anti-idiotype serum and monoclonal antibodies. These reagents provide a new way to obtain more precise immunochemical characterization.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6431443

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN: 0361-7742


  12 in total

1.  Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid.

Authors:  M Arai; D Scandella; L W Hoyer
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

2.  A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding. Localization of its antigenic determinant to a nonadecapeptide at the amino terminus of the mature vWF polypeptide.

Authors:  W F Bahou; D Ginsburg; R Sikkink; R Litwiller; D N Fass
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

3.  Kappa/lambda immunoglobulin distribution in Graves' thyroid-stimulating antibodies. Simultaneous analysis of C lambda gene polymorphisms.

Authors:  R C Williams; N J Marshall; K Kilpatrick; J Montano; P M Brickell; M Goodall; P A Ealey; B Shine; A P Weetman; R K Craig
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

4.  Characterization of a monoclonal anti-idiotype antibody to human anti-factor VIII antibodies.

Authors:  B C Lubahn; H M Reisner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

5.  The diversity of the immune response to the A2 domain of human factor VIII.

Authors:  Rebecca C Markovitz; John F Healey; Ernest T Parker; Shannon L Meeks; Pete Lollar
Journal:  Blood       Date:  2013-01-24       Impact factor: 22.113

6.  Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments.

Authors:  C A Fulcher; S de Graaf Mahoney; J R Roberts; C K Kasper; T S Zimmerman
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

7.  Isolation and study of an acquired inhibitor of human coagulation factor V.

Authors:  M E Nesheim; W L Nichols; T L Cole; J G Houston; R B Schenk; K G Mann; E J Bowie
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

Review 8.  Characterization of factor VIII inhibitors.

Authors:  Midori Shima
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

9.  Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes.

Authors:  Justin D Walter; Rachel A Werther; Caileen M Brison; Rebecca K Cragerud; John F Healey; Shannon L Meeks; Pete Lollar; P Clint Spiegel
Journal:  Blood       Date:  2013-10-01       Impact factor: 22.113

10.  Subclass analysis of donor HLA-specific IgG in antibody-incompatible renal transplantation reveals a significant association of IgG4 with rejection and graft failure.

Authors:  Natasha Khovanova; Sunil Daga; Torgyn Shaikhina; Nithya Krishnan; James Jones; Daniel Zehnder; Daniel Mitchell; Robert Higgins; David Briggs; David Lowe
Journal:  Transpl Int       Date:  2015-09-01       Impact factor: 3.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.